ArticleEJIFCC2026
Unraveling the Need for standardization of Homocysteine Assay: Insights from the Results of External Quality Assurance.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homocysteine is an intermediate product of the biosynthesis of methionine and cysteine and a sulfhydryl-containing amino acid. The study aims to assess the difference between the estimated levels of homocysteine by different automated systems on Biorad External Quality Assurance Services samples and the imprecision of examination of homocysteine levels below the limit of detection in External Quality Assurance Services samples by proficiency testing providers. This study involves the analysis of Biorad External Quality Assurance Services sample reports of two cycles (cycles 10 and 11) for homocysteine level evaluation performance. Our study demonstrates the wide difference in the bias percentage of homocysteine levels when bias was calculated with the peer mean and the method mean. There was a substantial increase in bias percentage for the Siemens Advia Centaur XP machine for samples with levels of homocysteine below the limit of detection. Our study also demonstrated that Siemens Advia and Siemens Atellica were evidently underestimating homocysteine levels when compared with other platforms. The use of Standard Reference Material for traceability of calibrators will ensure the standardization of assays between different manufacturers. The variation observed in the External Quality Assurance Services results of homocysteine highlights the impending requirement of standardization of assays using Standard Reference Materials.
Indexed as
Identifiers
42699022PMC13543441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.